Key result
Catheter ablation plus AAD linked to ~50% lower major cardiovascular events vs AAD alone in AF with PH.
Why the study?
While catheter ablation is superior to AAD therapy in select AF populations, outcomes in patients with concurrent pulmonary hypertension remain poorly characterized.
Does catheter ablation plus anti-arrhythmic drug therapy reduce major adverse cardiovascular events and right heart failure in adults with atrial fibrillation and pulmonary hypertension compared to anti-arrhythmic drug therapy alone?
Cohort (n=19,518)
Yes
Does catheter ablation plus anti-arrhythmic drug therapy reduce major adverse cardiovascular events and right heart failure in adults with atrial fibrillation and pulmonary hypertension compared to anti-arrhythmic drug therapy alone?
In patients with atrial fibrillation and pulmonary hypertension, catheter ablation combined with anti-arrhythmic drugs is associated with significantly lower risks of MACE, right heart failure, and mortality compared to anti-arrhythmic drugs alone.
Answers are grounded in this paper and cite their sources.
Supports ablation over AAD in AF with PH; extends randomized evidence to this high-risk population.
Introduction Atrial fibrillation (AF) frequently coexists with pulmonary hypertension (PH) and is associated with clinical deterioration, right ventricular dysfunction, and increased mortality. While catheter ablation has demonstrated superiority over anti‐arrhythmic drug (AAD) therapy in select AF populations, outcomes in patients with concurrent PH remain poorly characterized. Methods We performed a retrospective cohort study using the TriNetX Research Network. Adults with AF and PH were identified and stratified by treatment with catheter ablation plus AAD or AAD therapy alone. After 1:1 propensity score matching for demographics, comorbidities, and medication use, 9759 patients were included in each cohort. The primary outcomes were major adverse cardiovascular events (MACE) and right heart failure. Secondary outcomes included all‐cause mortality, acute myocardial infarction (MI), and stroke. Kaplan–Meier models were used as the primary analysis, with Cox proportional hazards and E ‐value analysis as sensitivity. Competing risk analyses were performed using Fine‐Gray models. Results Ablation was associated with a 50% reduction in MACE (HR 0.497 [0.467, 0.528], p < 0.001) and 35% reduction in right heart failure (HR 0.647 [0.573, 0.732], p < 0.001). There were also significant reductions in all‐cause mortality (HR 0.469 [0.454, 0.488], p < 0.001) and stroke (HR 0.819 [0.728, 0.922], p = 0.001). There was no difference in acute MI (HR 0.982 [0.891, 1.082], p = 0.710). Findings were consistent across Cox sensitivity analyses, E ‐value analysis, and competing‐risk models. Conclusion In AF patients with PH, catheter ablation with AAD therapy was associated with substantially lower risks of adverse cardiovascular outcomes compared with AAD therapy alone. These findings suggest that catheter ablation is associated with lower risks of adverse cardiovascular outcomes in this high‐risk population.
No takes yet. Share an insight, caveat, or question.
Fahim et al. (2026) conducted a cohort in Atrial fibrillation and pulmonary hypertension (n=19,518). Catheter ablation plus anti-arrhythmic drug (AAD) vs. AAD therapy alone was evaluated on Major adverse cardiovascular events (MACE) (HR 0.497, 95% CI 0.467-0.528, p=<0.001). Catheter ablation plus AAD therapy was associated with a 50% reduction in major cardiovascular events compared with AAD therapy alone in AF patients with PH.
Synapse has enriched 10 related papers. Consider them for comparative context: